Compounds > dalteparin
Page last updated: 2024-10-18

dalteparin and Shock, Cardiogenic

dalteparin has been researched along with Shock, Cardiogenic in 3 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oudemans-van Straaten, HM1
van Schilfgaarde, M1
Molenaar, PJ1
Wester, JP1
Leyte, A1
Giugliano, RP1
Giraldez, RR1
Morrow, DA1
Antman, EM1
Gibson, CM1
Mohanavelu, S1
Murphy, SA1
McCabe, CH1
Braunwald, E1
Ellis, SG1
Armstrong, P1
Betriu, A1
Brodie, B1
Herrmann, H1
Montalescot, G1
Neumann, FJ1
Smith, JJ1
Topol, E1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328]Phase 414 participants (Actual)Interventional2007-02-28Completed
A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention [NCT00046228]Phase 32,461 participants (Actual)Interventional2002-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-Cause Mortality Through 1 Year

All-cause mortality through 1 year from randomization. (NCT00046228)
Timeframe: 1 year

Interventionparticipants (Number)
Primary PCI Group56
Abciximab Facilitated PCI Group60
Reteplase/Abciximab Facilitated PCI Group52

All-Cause Mortality Through 90 Days

All cause mortality occurred through 90 days from randomization. (NCT00046228)
Timeframe: 90 days

Interventionparticipants (Number)
Primary PCI Group36
Abciximab Facilitated PCI Group45
Reteplase/Abciximab Facilitated PCI Group43

Complications of MI as Defined in the Primary Outcome Measure Through 90 Days

The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization. (NCT00046228)
Timeframe: 90 Days

Interventionparticipants (Number)
Primary PCI Group72
Abciximab Facilitated PCI Group61
Reteplase/Abciximab Facilitated PCI Group61

Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7

(NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group139
Abciximab Facilitated PCI Group178
Reteplase/Abciximab Facilitated PCI Group271

Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7

All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee). (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group1
Abciximab Facilitated PCI Group0
Reteplase/Abciximab Facilitated PCI Group5

Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7

Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipant (Number)
Primary PCI Group55
Abciximab Facilitated PCI Group81
Reteplase/Abciximab Facilitated PCI Group118

Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7

Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group128
Abciximab Facilitated PCI Group122
Reteplase/Abciximab Facilitated PCI Group120

Subjects With Severe Thrombocytopenia Through Discharge/Day 7

Severe thrombocytopenia is defined as platelet count < 50,000 cells/μL. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group11
Abciximab Facilitated PCI Group16
Reteplase/Abciximab Facilitated PCI Group16

Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization

(NCT00046228)
Timeframe: 60 to 90 minutes

Interventionparticipants (Number)
Primary PCI Group75
Abciximab Facilitated PCI Group85
Reteplase/Abciximab Facilitated PCI Group108

The Composite of All-Cause Mortality or Complications of MI at 90 Days.

Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization). (NCT00046228)
Timeframe: 90 days

Interventionparticipants (Number)
Primary PCI Group86
Abciximab Facilitated PCI Group86
Reteplase/Abciximab Facilitated PCI Group81

Trials

3 trials available for dalteparin and Shock, Cardiogenic

ArticleYear
Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
    Critical care (London, England), 2009, Volume: 13, Issue:6

    Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; APACHE; Blood Coagulation; Critical Illness; Cross

2009
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Aged; Cause of Death; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage

2010
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Mo

2004